Our Pipeline

Advancing new potential treatments for certain GI diseases affecting millions of patients in need

  • Compound
  • Indication
  • PHASE I
  • PHASE II
  • PHASE III
  • Approval
  • Linzess® Partner

  • IBS-C or CIC in adults

    • Launched 12/12; sNDA for overall abdominal symptoms submitted Nov 2019
  • linaclotide Partner

  • IBS-C/FC in pediatrics

  • MD-7246 Partner

  • Abdominal pain associated with IBS-D

    • Phase II trial results targeted mid-2020

Status of selected key development programs as of February 25, 2020. Represents ongoing phase of development; does not correspond to completion of a particular phase.

Click here for LINZESS® full US Prescribing Information including BOXED WARNING.

Copyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.

You are now leaving www.IronwoodPharma.com.

This link will take you to a website to which our privacy policy does not apply. You are solely responsible for your interactions with that website.